Iridina Antibiotico (Tobramycin)

Tobramycin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and inhibition of protein synthesis. This action leads to bacterial cell death, effectively eliminating the pathogens responsible for ocular infections.

The dosing regimen for Iridina Antibiotico is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will provide instructions on the number of drops, frequency, and duration of treatment.

The safety of Tobramycin ophthalmic use in pregnancy and lactation has not been definitively established. Clinicians should weigh the potential benefits against any possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iridina Antibiotico (Tobramycin) belongs to the aminoglycoside class, offering strong activity against Gram‑negative bacteria. Compared with fluoroquinolone eye drops, it may have a narrower spectrum but is effective for organisms resistant to other classes. Choice depends on susceptibility patterns and clinician preference.

Store the ophthalmic solution below 25 °C in its original container, protecting it from light and moisture. Do not freeze. Keep the vial tightly sealed when not in use and discard any solution that appears discolored or contaminated.

The medication is applied as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., every 2–4 hours), and the total duration of therapy. Hands should be washed before instillation, and the dropper tip should avoid contact with the eye or surrounding tissues.

Serious adverse events, though rare, include corneal ulceration, allergic contact dermatitis, vision changes, and systemic ototoxicity or nephrotoxicity if significant absorption occurs. Patients should report any worsening of symptoms, severe eye pain, or systemic signs such as hearing loss promptly.

Patients with a known hypersensitivity to Tobramycin or other aminoglycosides should avoid this product. It is also contraindicated in viral or fungal eye infections, as it will not be effective and may delay appropriate treatment.